关注我国首个生物工程角膜的临床应用
Focus on the clinical application of the first artificial bioengineered cornea in China
摘要
角膜盲是我国第二大致盲原因,占盲人总数的1/4,其现状是发病率高、复明率低,而角膜供体匮乏和角膜病专业医师缺乏乃制约我国角膜盲复明的瓶颈.解决我国角膜盲最为关键的措施是寻找充足的角膜供体.2015年全球首个生物工程角膜通过我国食品药品管理局的批准,可替代人角膜供体行板层角膜移植术,这将极大缓解我国角膜供体匮乏的现状,同时可加速角膜病专业医师的培训和成长.该创新性研究成果的临床应用将极大促进我国角膜病的基础和临床研究,给更多角膜病盲人带来光明.
Corneal disease ranks second among blinding diseases in China,with the corneal blindness taking up one fourth of the blind population.It has a high incidence and a low rate of sight rehabilitation.The lack of cornea donors and the shortage of corneal specialists have become the bottleneck that hampers the development in curing corneal disease.It is of primal importance to find sufficient donor sources in order to alleviate the current situation.In 2015,the world's first artificial bioengineered cornea was approved by CFDA to be applied clinically as a substitute for human cornea in lamellar keratoplasty.It will not only relieve the cornea donor shortage,but will also spur the training and practices of corneal specialists.The application and clinical trials of such an innovative product will significantly boost fundamental and clinical researches in corneal disease in our country,helping more patients with corneal blindness to recover their sights.
Author:
Shi Weiyun
Xie Lixin
作者单位:
山东省眼科研究所,青岛,266071
年,卷(期):
2016, 52(3)
机标分类号:
R779.65
R318.08
R155.6
在线出版日期:
2016年4月21日